Drug Profile
Carbidopa/levodopa - Amneal Pharmaceuticals
Alternative Names: IPX-203; IPX-203 CD/LD extended-release capsules; IPX203 ER; IPX203 ER CD-LD; IPX203 extended-release capsulesLatest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Impax Pharmaceuticals
- Developer Amneal Pharmaceuticals; Impax Pharmaceuticals
- Class Antiasthmatics; Antiparkinsonians; Aromatic amino acids; Catecholamines; Hydrazines; Small molecules
- Mechanism of Action Decarboxylase inhibitors; Dopamine receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Parkinson's disease
Highest Development Phases
- Preregistration Parkinson's disease
Most Recent Events
- 27 Feb 2024 Amneal Pharmaceuticals enters into a licensing agreement with Zambon Biotech SA for IPX 203 in European Union, United Kingdom, and Switzerland
- 08 Feb 2024 Amneal Pharmaceuticals resubmits a complete response letter to the FDA for IPX 203 for Parkinson’s disease (Healthy volunteers)
- 25 Jan 2024 Carbidopa/levodopa licensed to Knight Therapeutics in Canada and Latin America for commercialization